UNITED STATES: LATEST INTERVIEWS MORE INTERVIEWS

"Based on our in vivo data for our lead CEACAM1/5 antibody YB-200 we have obtained orphan drug status from FDA for the treatment of liver cancer."
"We want to pioneer a commodity utility approach for needed areas of pharmaceutical manufacturing, and make that available as a sustainable platform that any country can start with and innovate from."
"Experienced CDMOs can provide companies with access to new formulation and technology methods that improve the bioavailability of difficult-to-formulate compounds."
"Companies should be ready to address hostile short-selling and unsolicited takeover bids, develop rapid responses to special meetings and activist demands, and vigorously engage with institutional shareholders, proxy advisory firms, and potential regulators."

UNITED STATES: LATEST ARTICLES

Protecting Supply Chains and Prosperity: The Case for Reducing US Dependency on Foreign Critical Minerals

October 12, 2022
Expert Opinion Article by Eric Mears, Vice President, Haley & Aldrich

Arizona Copper Production: Securing a Domestic Supply Chain

October 10, 2022
Arizona, leading the charge towards the green transition

Funding Environment: Life Sciences Enter the Mainstream

April 20, 2021
The past 12 months been transformative for the life science industry in USA, and GBR explores how the funding environment has evolved to provide the influx of capital to sustain its innovations.

UNITED STATES: RECENTLY RELEASED PUBLICATIONS

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENTLY PUBLISHED

United States Life Sciences 2023

In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.

PARTNER EVENTS